ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · EU licence (European Commission)

Tofacitinib (Inijaq)

Rheumatoid arthritis  Tofacitinib in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).  Tofacitinib can be given as… Show the full indication

Rheumatoid arthritis  Tofacitinib in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).  Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.   Psoriatic arthritis  Tofacitinib in combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.   Ankylosing spondylitis  Tofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy.   Ulcerative colitis  Tofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.   Juvenile idiopathic arthritis (JIA)  Tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in patients 2 years of age and older, who have responded inadequately to previous therapy with DMARDs.  Tofacitinib can be given in combination with methotrexate (MTX) or as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.

Generic
CHMP opinion 17 Sept 2026 → EU licence 12 Nov 2026 · Gedeon Richter Plc.

Research

Gastroenterology · J Crohns Colitis · 2026-08-05

Network meta-analysis of 16 retrospective cohort studies (3235 UC patients having colorectal surgery): preoperative ustekinumab (RR 0.29) and tofacitinib (RR 0.66) were associated with fewer 30-day complications than no advanced therapy; anti-TNF with more at 90 days (RR 1.20).

Meta-analysisn = 3,235
Hayek et al. Comparative risk of postoperative complications in ulcerative colitis patients following preoperative advanced therapies: a network meta-analysis with meta-regression

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.